Terumo Corp. (OTCMKTS:TRUMY – Get Free Report)’s share price hit a new 52-week low during trading on Monday . The stock traded as low as $14.03 and last traded at $14.55, with a volume of 17783 shares changing hands. The stock had previously closed at $14.64.
Terumo Stock Performance
The company has a current ratio of 2.51, a quick ratio of 1.46 and a debt-to-equity ratio of 0.07. The company has a market cap of $21.55 billion, a PE ratio of 24.26 and a beta of 0.75. The firm’s 50-day simple moving average is $15.57 and its two-hundred day simple moving average is $16.75.
Terumo (OTCMKTS:TRUMY – Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. The business had revenue of $1.86 billion during the quarter, compared to analysts’ expectations of $1.75 billion. Terumo had a net margin of 12.35% and a return on equity of 9.39%.
Terumo Company Profile
Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.
Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.
Featured Stories
- Five stocks we like better than Terumo
- Do not delete, read immediately
- How the Rich Retire
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- How Long Will $1M Last in Retirement?
- [No Brainer Gold Play]: “Show me a better investment.”
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
